Key result
Cardiac catheterization laboratory nonactivation for suspected STEMI was associated with higher 2-year all-cause mortality compared with activation.
Why the study?
Patients with suspected STEMI and cardiac catheterization laboratory nonactivation or cancellation reportedly have similar crude and higher adjusted risks of death versus activation, but reasons for these poor outcomes are unclear.
Does cardiac catheterization laboratory nonactivation increase all-cause death in patients with prehospital ECG STEMI criteria compared to CCL activation?
Cohort (n=1,033)
Does cardiac catheterization laboratory nonactivation increase all-cause death in patients with prehospital ECG STEMI criteria compared to CCL activation?
Patients with prehospital STEMI criteria who appropriately do not undergo cath lab activation have higher long-term mortality than those activated, driven primarily by noncardiovascular deaths.
Answers are grounded in this paper and cite their sources.
CCL nonactivation flags higher-risk suspected STEMI patients for closer follow-up; hypothesis-generating for triage refinement and noncardiac risk mitigation.
Background Patients with suspected ST-segment-elevation myocardial infarction (STEMI) and cardiac catheterization laboratory nonactivation (CCL-NA) or cancellation have reportedly similar crude and higher adjusted risks of death compared with those with CCL activation, though reasons for these poor outcomes are not clear. We determined late clinical outcomes among patients with prehospital ECG STEMI criteria who had CCL-NA compared with those who had CCL activation. Methods and Results We identified consecutive prehospital ECG transmissions between June 2, 2010 to October 6, 2016. Diagnoses according to the Fourth Universal Definition of myocardial infarction (MI), particularly rates of myocardial injury, were adjudicated. The primary outcome was all-cause death. Secondary outcomes included cardiovascular death/MI/stroke and noncardiovascular death. To explore competing risks, cause-specific hazard ratios (HRs) were obtained. Among 1033 included ECG transmissions, there were 569 (55%) CCL activations and 464 (45%) CCL-NAs (1.8% were inappropriate CCL-NAs). In the CCL activation group, adjudicated index diagnoses included MI (n=534, 94%, of which 99.6% were STEMI and 0.4% non-STEMI), acute myocardial injury (n=15, 2.6%), and chronic myocardial injury (n=6, 1.1%). In the CCL-NA group, diagnoses included MI (n=173, 37%, of which 61% were non-STEMI and 39% STEMI), chronic myocardial injury (n=107, 23%), and acute myocardial injury (n=47, 10%). At 2 years, the risk of all-cause death was higher in patients who had CCL-NA compared with CCL activation (23% versus 7.9%, adjusted risk ratio, 1.58, 95% CI, 1.24-2.00), primarily because of an excess in noncardiovascular deaths (adjusted HR, 3.56, 95% CI, 2.07-6.13). There was no significant difference in the adjusted risk for cardiovascular death/MI/stroke between the 2 groups (HR, 1.23, 95% CI, 0.87-1.73). Conclusions CCL-NA was not primarily attributable to missed STEMI, but attributable to "masquerading" with high rates of non-STEMI and myocardial injury. These patients had worse late outcomes than patients who had CCL activation, mainly because of higher rates of noncardiovascular deaths.
No takes yet. Share an insight, caveat, or question.
Faour et al. (2022) conducted a cohort in Suspected ST-segment-elevation myocardial infarction (STEMI) (n=1,033). Cardiac catheterization laboratory nonactivation (CCL-NA) vs. Cardiac catheterization laboratory (CCL) activation was evaluated on All-cause death (adjusted risk ratio 1.58, 95% CI 1.24-2.00). Cardiac catheterization laboratory nonactivation for suspected STEMI was associated with higher 2-year all-cause mortality compared with activation.
Synapse has enriched 10 related papers. Consider them for comparative context: